Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Trial of Encorafenib, Cetuximab, and Nivolumab in Microsatellite Stable BRAFV600E Metastatic Colorectal Cancer (BMS-MDACC CA209-8P6/ARRAY IST-818-101X)

NCT04017650 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT04017650
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04017650 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Trial of Encorafenib, Cetuximab, and Nivolumab in Microsatellite Stable BRAFV600E Metastatic Colorectal Cancer (BMS-MDACC CA209-8P6/ARRAY IST-818-101X)
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
June 14, 2019
Completion date
December 30, 2027
Enrollment
38 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

braf np_004324.2:p.v600e, metastatic colon adenocarcinoma, metastatic microsatellite stable colorectal carcinoma, metastatic rectal adenocarcinoma, progressive disease, recurrent colorectal carcinoma, stage iii colorectal cancer ajcc v8, stage iiia colorectal cancer ajcc v8, stage iiib colorectal cancer ajcc v8, stage iiic colorectal cancer ajcc v8, stage iv colorectal cancer ajcc v8, stage iva colorectal cancer ajcc v8, stage ivb colorectal cancer ajcc v8, stage ivc colorectal cancer ajcc v8, unresectable colon adenocarcinoma, unresectable rectal adenocarcinoma